192 related articles for article (PubMed ID: 8898542)
1. Isoniazid hepatotoxicity after orthotopic liver transplantation.
Schluger LK; Sheiner PA; Jonas M; Guarrera JV; Fiel IM; Meyers B; Berk PD
Mt Sinai J Med; 1996; 63(5-6):364-9. PubMed ID: 8898542
[TBL] [Abstract][Full Text] [Related]
2. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis.
O'Brien RJ; Long MW; Cross FS; Lyle MA; Snider DE
Pediatrics; 1983 Oct; 72(4):491-9. PubMed ID: 6604257
[TBL] [Abstract][Full Text] [Related]
5. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens.
Meyers BR; Papanicolaou GA; Sheiner P; Emre S; Miller C
Transplantation; 2000 Jan; 69(1):64-9. PubMed ID: 10653382
[TBL] [Abstract][Full Text] [Related]
6. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.
Farrell FJ; Keeffe EB; Man KM; Imperial JC; Esquivel CO
Dig Dis Sci; 1994 Oct; 39(10):2255-9. PubMed ID: 7924752
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid].
Xing T; Chen J; Zhang G
Zhonghua Jie He He Hu Xi Za Zhi; 1997 Feb; 20(1):33-5. PubMed ID: 10072800
[TBL] [Abstract][Full Text] [Related]
11. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.
Ichai P; Saliba F; Antoun F; Azoulay D; Sebagh M; Antonini TM; Escaut L; Delvart V; Castaing D; Samuel D
Liver Transpl; 2010 Oct; 16(10):1136-46. PubMed ID: 20879012
[TBL] [Abstract][Full Text] [Related]
12. Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin.
Krishnaswamy K; Prasad CE; Murthy KJ
Trop Geogr Med; 1991; 43(1-2):156-60. PubMed ID: 1750106
[TBL] [Abstract][Full Text] [Related]
13. Importance of surveillance mycobacterial cultures after liver transplantation.
Torre-Cisneros J; de la Mata M; Rufian S; Villanueva Marcos JL; Gutierrez Aroca J; Casal M; Miño G; Pera C
Transplantation; 1995 Nov; 60(9):1054-5. PubMed ID: 7491683
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis during rifampicin and isoniazid treatment of a patient with generalized tuberculosis].
Volosevich GV
Probl Tuberk; 1989; (9):72-3. PubMed ID: 2587561
[No Abstract] [Full Text] [Related]
15. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
16. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
Ziakas PD; Mylonakis E
Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hepatotoxicity induced by antituberculosis drugs.
Devoto FM; González C; Iannantuono R; Serra HA; González CD; Sáenz C
Acta Physiol Pharmacol Ther Latinoam; 1997; 47(4):197-202. PubMed ID: 9504179
[TBL] [Abstract][Full Text] [Related]
19. [Liver damage from tuberculosis treatment].
Keiner F
Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
[No Abstract] [Full Text] [Related]
20. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
Chest; ; . PubMed ID: 17166986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
